Proteomics identifies EGF‐like domain multiple 7 as a potential therapeutic target for epidermal growth factor receptor‐positive glioma

Wang, Feiyifan; Wanggou, Siyi; Cao, Hang; Jiang, Nian; Yang, Qi; Huang, Qi; Huang, Chunhai; Li, Xuejun

doi:10.1002/cac2.12092

Cited by 6 publications

(3 citation statements)

References 46 publications

(59 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EGF is a growth factor that stimulates cellular proliferation and differentiation ( 30 ). EGF binds to the extracellular domain of EGFR and induces its dimerization, activating its intrinsic kinase activity ( 34 , 35 ). EGF/EGFR signaling has been recognized as an important molecular target in cancer therapy.…”

Section: Discussionmentioning

confidence: 99%

Proteome profiling of formalin‑fixed, paraffin‑embedded lung adenocarcinoma tissues using a tandem mass tag‑based quantitative proteomics approach

et al. 2021

View full text Add to dashboard Cite

Over the past few decades, increasing efforts have been made to improve the understanding of, and treatment options for, lung adenocarcinoma (LUAD). However, considering the heterogeneity of LUAD, precise proteomics-based characterization at the molecular level is an urgent clinical requirement for effective treatment. Formalin-fixed, paraffin-embedded (FFPE) tissue is a good option as the working tool for proteomics studies. The present study aimed to obtain a global protein profile using LUAD FFPE tissue samples. Using a quantitative proteomics approach, the study revealed that 360 proteins were significantly more highly expressed in LUAD than in adjacent nontumor lung tissues. Also, 19 differentially expressed membrane proteins were found to be primarily responsible for immune processes. Epidermal growth factor (EGF)-like domain and laminin EGF domain showed markedly different expression levels between cancer tissues and tumor-adjacent normal tissues. Furthermore, Gene Ontology functional enrichment analysis showed that significantly upregulated proteins were associated with the endoplasmic reticulum lumen, protein disulfide isomerase activity, vitamin binding, cell cycle G 1 /S phase transition, to name but a few. Also, numerous kinases and post-translational modification enzymes were significantly upregulated across all eight LUAD samples compared with paracarcinoma tissues. Proteomics analysis revealed that AAA domain containing 3A (ATAD3a), a member of the ATPase family, was highly expressed in LUAD tissues, which was supported by immunohistochemical analysis. Furthermore, the study confirmed that ATAD3a enhanced the cisplatin sensitivity of LUAD cells. Collectively, the findings of the present study provide new potential candidate targets in patients with LUAD, and may aid auxiliary LUAD diagnosis and surveillance in a noninvasive manner.

show abstract

Section: Discussionmentioning

confidence: 99%

Proteome profiling of formalin‑fixed, paraffin‑embedded lung adenocarcinoma tissues using a tandem mass tag‑based quantitative proteomics approach

et al. 2021

View full text Add to dashboard Cite

show abstract

“… 62 Quantitative proteomics was adopted to characterize 200 paired EGFR-positive and EGFR-negative glioma tissues of all pathological types, and EGF-like domain multiple 7 (EGFL7) was identified as a potential diagnostic biomarker and therapeutic target. 79 …”

Section: Discovering Drug Targets With Quantitative Proteomicsmentioning

confidence: 99%

Quantitative proteomics characterization of cancer biomarkers and treatment

Yang

Shi

Zhang

et al. 2021

Molecular Therapy - Oncolytics

View full text Add to dashboard Cite

Cancer accounted for 16% of all death worldwide in 2018. Significant progress has been made in understanding tumor occurrence, progression, diagnosis, treatment, and prognosis at the molecular level. However, genomics changes cannot truly reflect the state of protein activity in the body due to the poor correlation between genes and proteins. Quantitative proteomics, capable of quantifying the relatively different protein abundance in cancer patients, has been increasingly adopted in cancer research. Quantitative proteomics has great application potentials, including cancer diagnosis, personalized therapeutic drug selection, real-time therapeutic effects and toxicity evaluation, prognosis and drug resistance evaluation, and new therapeutic target discovery. In this review, the development, testing samples, and detection methods of quantitative proteomics are introduced. The biomarkers identified by quantitative proteomics for clinical diagnosis, prognosis, and drug resistance are reviewed. The challenges and prospects of quantitative proteomics for personalized medicine are also discussed.

show abstract

“…The formation and development of glioma is a complex process caused by abnormal genetic changes or epigenetic abnormalities (13). The etiology of glioma has been partially elucidated but remains unclear (14)(15)(16)(17). With the progress of genomic association research and other technologies, genetic mutation has attracted more and more attention as the cause of glioma formation.…”

Section: Introductionmentioning

confidence: 99%

KRAS gene polymorphisms are associated with the risk of glioma: a two-center case-control study

Guan

et al. 2021

Transl Pediatr

View full text Add to dashboard Cite

Background: Glioma, also known as neuroglioma, is the most common primary tumors of the central nervous system. Many previous studies have reported associations between RAS gene polymorphisms and multiple tumors. However, the role of RAS gene polymorphisms on glioma risk has not been investigated. Methods: We conducted a two-center case-control study to investigate whether the RAS gene polymorphisms predispose individuals to gliomas in 248 healthy controls and 191 glioma patients. RAS gene polymorphisms (rs12587 G>T, rs7973450 A>G, rs7312175 G>A in KRAS, rs2273267 A>T in NRAS) were genotyped by the TaqMan assay. The relationship between RAS gene functional single nucleotide polymorphisms (SNPs) and the risk of glioma was evaluated based on odds ratios (ORs) and 95% confidence intervals (CIs). Results: Individuals with KRAS rs7312175 GA genotype were more likely to develop glioma than those with GG genotype (adjusted OR =1.66, 95% CI: 1.05-2.64, P=0.030). However, the other three SNPs could not affect glioma risk. In stratified analysis of age, gender, subtypes, and clinical stages, rs7312175 GA carriers were more likely to develop glioma in the following subgroups: children less than 60 months, tumor derived from the astrocytic tumors, and clinical stages I. Conclusions: The study showed that polymorphism rs7312175 GA in the KRAS gene was associated with increased glioma susceptibility. Further investigation is warranted to confirm these findings and to better elucidate the involved biological pathways.

show abstract

Proteomics identifies EGF‐like domain multiple 7 as a potential therapeutic target for epidermal growth factor receptor‐positive glioma

Cited by 6 publications

References 46 publications

Proteome profiling of formalin‑fixed, paraffin‑embedded lung adenocarcinoma tissues using a tandem mass tag‑based quantitative proteomics approach

Proteome profiling of formalin‑fixed, paraffin‑embedded lung adenocarcinoma tissues using a tandem mass tag‑based quantitative proteomics approach

Quantitative proteomics characterization of cancer biomarkers and treatment

KRAS gene polymorphisms are associated with the risk of glioma: a two-center case-control study

Contact Info

Product

Resources

About